Evidence map›Paper›PMID 16000412›Full record

Trial reportJournal of clinical microbiology2005

Evaluation of PCR for diagnosis of Indian kala-azar and assessment of cure.

R Maurya, R K Singh, B Kumar, P Salotra, M Rai, S Sundar

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in Journal of clinical microbiology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Amphotericin B Deoxycholate Treatment of Post-Kala-Azar Dermal Leishmaniasis in India.The American journal of tropical medicine and hygiene · 2024
    Article
  6. Article
  7. Article
  8. IFN-γCellular immunology · 2021
    Article
  9. A critical review of the applicability of serological screening for Leishmaniasis in blood banks in Brazil.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2021
    Review
  10. Review
  11. Molecular Diagnosis of Visceral Leishmaniasis.Molecular diagnosis & therapy · 2018
    Review
  12. Serological and Molecular Analysis ofThe American journal of tropical medicine and hygiene · 2017
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Emergence of a new focus of visceral leishmaniasis due to Leishmania infantum in Golestan Province, north-eastern of Iran.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2014
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

R MauryaInfectious Diseases Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, 6 SK Gupta, Nagar, Lanka, Varanasi 221 005, India.
R K Singh
B Kumar
P Salotra
M Rai
S Sundar
Banaras Hindu University · INInstitute of Medical Sciences · INNational Institute of Pathology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study was done to evaluate PCR with Ld1 primers for the diagnosis of Indian visceral leishmaniasis (VL) and to assess its role in prediction of the disease outcome. The PCR assay was performed with DNA isolated from the peripheral blood of parasitologically confirmed cases of VL before the initiation of treatment, just after the end of treatment, and at 3 and 6 months of follow-up. The pretreatment PCR result was positive for 100 of 101 patients (sensitivity, 99%; confidence interval [CI], 94 to 100%). None of the 150 negative controls tested were PCR positive (specificity, 100%; CI, 96.8 to 100%). Of 60 patients who were treated at our center, 51 (85%; CI, 73 to 93%) became negative immediately after treatment and continued to be negative at 3 and 6 months of follow-up. At the 3-month follow-up, two of the remaining nine patients were PCR positive, making 58 (96.7%; CI, 87 to 100%) patients PCR negative. At the 6-month follow-up, all patients became PCR negative. One patient who was PCR negative immediately after the end of treatment relapsed 11 months later. This limited prospective study with VL patients suggests that the PCR assay is a highly sensitive and specific (99% and 100%, respectively) tool for the diagnosis of VL. In the majority of patients, it can identify a successful disease outcome; however, its translation into the field setting remains a major challenge.

Indexed as

AnimalsAntiprotozoal AgentsDNA, ProtozoanHumansIndiaLeishmania donovaniLeishmaniasis, VisceralPolymerase Chain ReactionSensitivity and SpecificityTreatment OutcomeAntiprotozoal AgentsDNA, Protozoan

Identifiers

PMID16000412
PMCPMC1169152
OpenAlexW2146882401

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.